Clinical Trial: A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors

U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07159828) titled 'A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors' on Aug. 22.

Brief Summary: The goal of this clinical trial is to learn more about the side effects and best dose of AXN-2510 in adults with advanced solid tumors. The main questions it aims to answer are:

* What are the side effects of AXN-2510?

* Which is the best tolerated dose of AXN-2510?

* How long does AXN-2510 stay in your body?

Participants will receive AXN-2510 every 3 weeks. Participants will visit the clinic for checkups and tests several days during the first and third doses, and once every 3 weeks for other doses.

Study Start Date: S...